ARL17 Inhibitors

ARL17 inhibitors of the PI3K/Akt pathway, such as Wortmannin and LY294002, can alter cellular growth and survival signals, thus potentially adjusting the regulatory context for ARL17. Similarly, mTOR inhibitors like Rapamycin have broad effects on cell growth and metabolism, which can have downstream effects on proteins like ARL17. Inhibitors targeting the MAPK pathway, such as PD98059, SP600125, SB203580, and U0126, can impact cellular responses to various stimuli, including stress, growth factors, and cytokines, thus creating an indirect effect on ARL17's activity.

Gefitinib and Dasatinib, which target growth factor receptors and tyrosine kinases respectively, can change the signaling landscape of a cell by inhibiting pathways that may be upstream or parallel to those involving ARL17. Y-27632, as a ROCK inhibitor, affects the cytoskeleton and related signaling, potentially influencing ARL17's function in cellular structure and motility. Additionally, Go6983, by inhibiting protein kinase C, can affect numerous signaling pathways, possibly altering the functional state of ARL17. These compounds represent a chemical toolkit that can indirectly influence the function of ARL17 by modulating the activity of related signaling pathways or cellular processes.